Therapeutic drug monitoring of nortriptyline in smoking cessation: A multistudy analysis

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 3, 2008, Pages 436-442

  Mooney, M E ^a   Reus, V I ^b   Gorecki, J ^b   Hall, S M ^b   Humfleet, G L ^b   Muoz R F ^b   Delucchi, K ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORTRIPTYLINE;

ADULT; ARTICLE; ASIAN; BLURRED VISION; CIGARETTE SMOKING; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; FEMALE; HAND TREMOR; HUMAN; MALE; NEGRO; PRIORITY JOURNAL; SMOKING CESSATION; XEROSTOMIA;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTRIPTYLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION;

EID: 39449135841     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100307     Document Type: Article

References (52)

1. Wagena, E.J., Knipschild, P. & Zeegers, M.P. Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 100, 317-326 (2005).
2. Hughes, J.R., Stead, L.F. & Lancaster, T. Nortriptyline for smoking cessation: a review. Nicotine Tob. Res. 7, 491-499 (2005).
3. Alexanderson, B. Pharmacokinetics of nortriptyline in man after single and multiple oral doses: the predictability of steady-state plasma concentrations from single-dose plasma-level data. Eur. J. Clin. Pharmacol. 4, 82-91 (1972).
4. Kragh-Sorensen, P., Hansen, C.E., Baastrup, P.C. & Hvidberg, E.F. Self-inhibiting action of nortriptylin's antidepressive effect at high plasma levels: a randomized double-blind study controlled by plasma concentrations in patients with endogenous depression. Psychopharmacologia 45, 305-312 (1976).
5. Hall, S.M., Humfleet, G.L., Reus, V.I., Munoz, R.F. & Cullen, J. Extended nortriptyline and psychological treatment for cigarette smoking. Am. J. Psychiatry 161, 2100-2107 (2004).
6. Hall, S.M., Humfleet, G.L., Reus, V.I., Munoz, R.F., Hartz, D.T. & Maude-Griffin, R. Psychological intervention and antidepressant treatment in smoking cessation. Arch. Gen. Psychiatry 59, 930-936 (2002).
7. Hall, S.M. et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry 55, 683-690 (1998).
8. Prochazka, A.V., Kick, S., Steinbrunn, C., Miyoshi, T. & Fryer, G.E. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch. Intern. Med. 164, 2229-2233 (2004).
9. Prochazka, A.V., Weaver, M.J., Keller, R.T., Fryer, G.E., Licari, P.A. & Lofaso, D. A randomized trial of nortriptyline for smoking cessation. Arch. Intern. Med. 158, 2035-2039 (1998).
10. Razavi, D. & Mendlewicz, J. Tricyclic antidepressant plasma levels: the state of the art and clinical prospects. Neuropsychobiology 8, 73-85 (1982).
11. Risch, S.C., Kalin, N.H., Janowsky, D.S. & Huey, L.Y. Indications and guidelines for plasma tricyclic antidepressant concentration monitoring. J. Clin. Psychopharmacol. 1, 59-63 (1981).
12. Hughes, J.R. & Hatsukami, D. Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry 43, 289-294 (1986).
13. Tsoh, J.Y., Humfleet, G.L., Munoz, R.F., Reus, V.I., Hartz, D.T. & Hall, S.M. Development of major depression after treatment for smoking cessation. Am. J. Psychiatry 157, 368-374 (2000).
14. Asberg, M., Cronholm, B., Sjoqvist, F. & Tuck, D. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 3, 331-334 (1971).
15. Jackson, P.H., Stapleton, J.A., Russell, M.A. & Merriman, R.J. Nicotine gum use and outcome in a general practitioner intervention against smoking. Addict. Behav. 14, 335-341 (1989).
16. Alexanderson, B., Evans, D.A. & Sjoqvist, F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. BMJ 4, 764-768 (1969).
17. Bertilsson, L., Dahl, M.L. & Tybring, G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr. Scand. Suppl. 391, 14-21 (1997).
18. Jerling, M., Merle, Y., Mentre, F. & Mallet, A. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 - an evaluation with the nonparametric maximum likelihood method. Br. J. Clin. Pharmacol. 38, 453-462 (1994).
19. Lin, K.M., Poland, R.E., Smith, M.W., Strickland, T.L. & Mendoza, R. Pharmacokinetic and other related factors affecting psychotropic responses in Asians. Psychopharmacol. Bull. 27, 427-439 (1991).
20. Strickland, T.L., Ranganath, V., Lin, K.M., Poland, R.E., Mendoza, R. & Smith, M.W. Psychopharmacologic considerations in the treatment of black American populations. Psychopharmacol. Bull. 27, 441-448 (1991).
21. Ziegler, V.E., Knesevich, J.W., Wylie, L.T. & Biggs, J.T. Sampling time, dosage schedule, and nortriptyline plasma levels. Arch. Gen. Psychiatry 34, 613-615 (1977).
22. Kishimoto, A. & Hollister, L.E. Nortriptyline kinetics in Japanese and Americans. J. Clin. Psychopharmacol. 4, 171-172 (1984).
23. Pi, E.H., Tran-Johnson, T.K., Walker, N.R., Cooper, T.B., Suckow, R.F. & Gray, G.E. Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacol. Bull. 25, 483-487 (1989).
24. Rudorfer, M.V., Lane, E.A., Chang, W.H., Zhang, M.D. & Potter, W.Z. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br. J. Clin. Pharmacol. 17, 433-440 (1984).
25. Bathum, L., Skjelbo, E., Mutabingwa, T.K., Madsen, H., Horder, M. & Brosen, K. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br. J. Clin. Pharmacol. 48, 395-401 (1999).
26. Bradford, L.D., Gaedigk, A. & Leeder, J.S. High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data. Psychopharmacol. Bull. 34, 797-804 (1998).
27. Bradford, L.D. & Kirlin, W.G. Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology. Int. J. Neuropsychopharmcol. 1, 173-185 (1998).
28. Droll, K., Bruce-Mensah, K., Otton, S.V., Gaedigk, A., Sellers, E.M. & Tyndale, R.F. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 8, 325-333 (1998).
29. Evans, W.E., Relling, M.V., Rahman, A., McLeod, H.L., Scott, E.P. & Lin, J. S. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J. Clin. Invest. 91, 2150-2154 (1993).
30. Shimoda, K., Morita, S., Hirokane, G., Yokono, A., Someya, T. & Takahashi, S. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. Pharmacol. Toxicol. 86, 245-249 (2000).
31. Linnoila, M., George, L., Guthrie, S. & Leventhal, B. Effect of alcohol consumption and cigarette smoking on antidepressant levels of depressed patients. Am. J. Psychiatry 138, 841-842 (1981).
32. Perry, P.J., Browne, J.L., Prince, R.A., Alexander, B. & Tsuang, M.T. Effects of smoking on nortriptyline plasma concentrations in depressed patients. Ther. Drug Monit. 8, 279-284 (1986).
33. Norman, T.R., Burrows, G.D., Maguire, K.P., Rubinstein, G., Scoggins, B.A. & Davies, B. Cigarette smoking and plasma nortriptyline levels. Clin. Pharmacol. Ther. 21, 453-456 (1977).
34. Olesen, O.V. & Linnet, K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab. Dispos. 25, 740-744 (1997).
35. Edwards, R.J. et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos. 31, 282-288 (2003).
36. Rodriguez-Antona, C., Jover, R., Gomez-Lechon, M.J. & Castell, J.V. Quantitative RT-PCR measurement of human cytochrome P-450s: application to drug induction studies. Arch. Biochem. Biophys. 376, 109-116 (2000).
37. Schrenk, D., Brockmeier, D., Morike, K., Bock, K.W. & Eichelbaum, M. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur. J. Clin. Pharmacol. 53, 361-367 (1998).
38. Suzuki, T. et al. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiol. Infect. 135, 171-176 (2007).
39. Blackwell, B. Antidepressant drugs: side effects and compliance. J. Clin. Psychiatry 43(11 Part 2): 14-21 (1982).
40. Wagena, E.J., Knipschild, P.G., Huibers, M.J., Wouters, E.F. & van Schayck, C.P. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch. Intern. Med. 165, 2286-2292 (2005).
41. da Costa, C.L., Younes, R.N. & Lourenco, M.T. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 122, 403-408 (2002).
42. Asberg, M., Cronholm, B., Sjoqvist, F. & Tuck, D. Correlation of subjective side effects with plasma concentrations of nortriptyline. BMJ 4, 18-21 (1970).
43. Ziegler, V.E., Taylor, J.R., Wetzel, R.D. & Biggs, J.T. Nortriptyline plasma levels and subjective side effects. Br. J. Psychiatry 132, 53-60 (1978).
44. Rabkin, J.G. & Markowitz, J.S. Side effect assessment with SAFTEE: pilot study of the instrument. Psychopharmacol. Bull. 22, 389-396 (1986).
45. Ezzati, M. & Lopez, A.D. Estimates of global mortality attributable to smoking in 2000. Lancet 362, 847-852 (2003).
46. Ozdemir, V. et al. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin. Pharmacother. 7, 119-133 (2006).
47. Perry, P.J. et al. Relationship of free nortriptyline levels to therapeutic response. Acta Psychiatr. Scand. 72, 120-125 (1985).
48. Hughes, J.R., Keely, J.P., Niaura, R.S., Ossip-Klein, D.J., Richmond, R.L. & Swan, G.E. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob. Res. 5, 13-25 (2003).
49. Heatherton, T.F., Kozlowski, L.T., Frecker, R.C. & Fagerstrom, K.O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 86, 1119-1127 (1991).
50. McNair, D., Lorr, M. & Droppleman, L. Manual for Profile of Mood States (Edits, San Diego, CA, 1981).
51. Beck, A.T., Ward, C.H., Mendelson, M., Mock, J. & Erbaugh, J. An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561-571 (1961).
52. SAS Institute Inc. The SAS System for Windows 9.13 edn. (SAS Institute Inc., Cary, NC, 2005).